Success Metrics

Active Trials

2(40%)

Phase Distribution

Ph phase_1

60%

Ph phase_2

40%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution5 total trials

Phase 1Safety & dosage

3(60.0%)

Phase 2Efficacy & side effects

2(40.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(4)

Terminated(1)

Detailed Status

Recruiting2

Not yet recruiting2

Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

N/A

Most Advanced

Phase 2

Trials by Phase

Phase 13 (60.0%)

Phase 22 (40.0%)

Trials by Status

recruiting240%

not_yet_recruiting240%

withdrawn120%

Recent Activity

2 active trials

Showing 5 of 5

withdrawnphase_1

A Phase 1 Study Of FLAG Chemotherapy In Combination With Lisaftoclax And Pelcitoclax In Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia

NCT07428486

not_yet_recruitingphase_2

Efficacy and Safety of Lisaftoclax (APG-2575) Monotherapy in Patients With Indolent Lymphoma

NCT07459608

not_yet_recruitingphase_1

Lisatoclax Plus R-CHOP or Pola-R-CHP in Untreated DLBCL: A Phase Ib/II Study

NCT07398638

recruitingphase_2

Pirtobrutinib, Lisaftoclax, and Rituximab in the Treatment of R/R DLBCL

NCT07255963

recruitingphase_1

Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLL

NCT04215809

Clinical Trials (5)

Showing 5 of 5 trials

NCT07428486Phase 1

A Phase 1 Study Of FLAG Chemotherapy In Combination With Lisaftoclax And Pelcitoclax In Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia

Withdrawn

NCT07459608Phase 2

Efficacy and Safety of Lisaftoclax (APG-2575) Monotherapy in Patients With Indolent Lymphoma

Not Yet Recruiting

NCT07398638Phase 1

Lisatoclax Plus R-CHOP or Pola-R-CHP in Untreated DLBCL: A Phase Ib/II Study

Not Yet Recruiting

NCT07255963Phase 2

Pirtobrutinib, Lisaftoclax, and Rituximab in the Treatment of R/R DLBCL

Recruiting

NCT04215809Phase 1

Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLL

Recruiting

All 5 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 5